Idera Pharmaceuticals Inc (IDRA)

[CHM_760]

Idera +6.3% AH after presenting IMO-8400 data • 7:02 PM
Eric Jhonsa, SA News Editor

Idera (NASDAQ:IDRA) states clinical safety data for its IMO-8400 B-cell lymphoma drug supports "dose escalation in ongoing Phase 1/2 trials." In addition, preclinical data shows the potential for a combination therapy featuring IMO-8400 and rituximab (a monoclonal antibody).
If all goes as planned, Idera expects to receive final 24-week safety and clinical activity data for an Phase 1/2 dose escalation trial in 2H15.
Shares rose 9.2% in regular trading after Idera provided positive preclinical data for its IMO-2055 cancer drug.